Cargando…

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abouzayed, Ayman, Tano, Hanna, Nagy, Ábel, Rinne, Sara S., Wadeea, Fadya, Kumar, Sharmishtaa, Westerlund, Kristina, Tolmachev, Vladimir, Eriksson Karlström, Amelie, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594083/ https://www.ncbi.nlm.nih.gov/pubmed/33081166 http://dx.doi.org/10.3390/pharmaceutics12100977

Ejemplares similares

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26
por: Rinne, Sara S., et al.
Publicado: (2021)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
por: Baun, Christina, et al.
Publicado: (2020)

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
por: Abouzayed, Ayman, et al.
Publicado: (2023)

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2017)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

GRPR-targeting radiotheranostics for breast cancer management
por: D’Onofrio, Alice, et al.
Publicado: (2023)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting
por: Damiana, T. S. T., et al.
Publicado: (2023)

Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers
por: D’Onofrio, Alice, et al.
Publicado: (2022)

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
por: Varasteh, Zohreh, et al.
Publicado: (2013)

GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI
por: Pu, Fan, et al.
Publicado: (2015)

The Gastrin-Releasing Peptide Receptor (GRPR) in the Spinal Cord as a Novel Pharmacological Target
por: Takanami, Keiko, et al.
Publicado: (2014)

Dose Rate Effects on the Selective Radiosensitization of Prostate Cells by GRPR-Targeted Gold Nanoparticles
por: Marques, Ana, et al.
Publicado: (2022)

Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements
por: Santos, Joana, et al.
Publicado: (2015)

Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical
por: Ghosh, Arijit, et al.
Publicado: (2019)

[(99m)Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
por: Nock, Berthold A., et al.
Publicado: (2021)

Pain Inhibits GRPR Neurons via GABAergic Signaling in the Spinal Cord
por: Bardoni, Rita, et al.
Publicado: (2019)

PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
por: Rybalov, Maxim, et al.
Publicado: (2014)

Oxytocin Elicits Itch Scratching Behavior via Spinal GRP/GRPR System
por: Guo, Jing, et al.
Publicado: (2020)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

In Vivo Biodistribution and Efficacy Evaluation of NeoB, A Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
por: Montemagno, Christopher, et al.
Publicado: (2021)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics
por: Abouzayed, Ayman, et al.
Publicado: (2023)

(18)F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging
por: Yang, Min, et al.
Publicado: (2011)

Role of GRPR in Acupuncture Intervention in the “Itch-scratch Vicious Cycle” Spinal Circuit of Chronic Pruritus
por: Liu, Jia-jia, et al.
Publicado: (2023)

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer
por: Bakker, Ingrid L., et al.
Publicado: (2018)

PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [(68)Ga]Ga-NODAGA-AMBA and [(44)Sc]Sc-NODAGA-AMBA
por: Kálmán-Szabó, Ibolya, et al.
Publicado: (2022)

Comparative Evaluation of Novel (177)Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
por: Tano, Hanna, et al.
Publicado: (2021)

(68)Ga-Labeled [Thz(14)]Bombesin(7–14) Analogs: Promising GRPR-Targeting Agonist PET Tracers with Low Pancreas Uptake
por: Wang, Lei, et al.
Publicado: (2023)

B-type natriuretic peptide is neither itch-specific nor functions upstream of the GRP-GRPR signaling pathway
por: Liu, Xian-Yu, et al.
Publicado: (2014)

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
por: Honarvar, Hadis, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2mss1oib4296uhpkdlbi0lt9bj